These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 28245774)
21. The gain-of-function variant allele CYP2C19*17: a double-edged sword between thrombosis and bleeding in clopidogrel-treated patients. Li Y; Tang HL; Hu YF; Xie HG J Thromb Haemost; 2012 Feb; 10(2):199-206. PubMed ID: 22123356 [TBL] [Abstract][Full Text] [Related]
22. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. Collet JP; Hulot JS; Cuisset T; Rangé G; Cayla G; Van Belle E; Elhadad S; Rousseau H; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Barthélémy O; Beygui F; Silvain J; Vicaut E; Montalescot G; Eur J Clin Pharmacol; 2015 Nov; 71(11):1315-24. PubMed ID: 26265231 [TBL] [Abstract][Full Text] [Related]
23. Association between CYP2C19 Polymorphisms and Outcomes in Cerebral Endovascular Therapy. Lin M; Todaro M; Chan J; Churilov L; Zhu WS; Ramdave S; Mitchell PJ; Dowling RJ; Kwan P; Yan B AJNR Am J Neuroradiol; 2016 Jan; 37(1):108-13. PubMed ID: 26338921 [TBL] [Abstract][Full Text] [Related]
24. Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population. Subraja K; Dkhar SA; Priyadharsini R; Ravindra BK; Shewade DG; Satheesh S; Sridhar MG; Narayan SK; Adithan C Eur J Clin Pharmacol; 2013 Mar; 69(3):415-22. PubMed ID: 22955794 [TBL] [Abstract][Full Text] [Related]
25. Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention. Komosa A; Siller-Matula JM; Lesiak M; Michalak M; Kowal J; Mączyński M; Siniawski A; Mularek-Kubzdela T; Wiśniewski S; Grajek S Thromb Res; 2016 Feb; 138():49-54. PubMed ID: 26826508 [TBL] [Abstract][Full Text] [Related]
26. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746 [TBL] [Abstract][Full Text] [Related]
27. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219 [TBL] [Abstract][Full Text] [Related]
28. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study. Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612 [TBL] [Abstract][Full Text] [Related]
29. Bedside testing of CYP2C19 gene for treatment of patients with PCI with antiplatelet therapy. Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Claassens DMF; Ten Berg JM; Asselbergs FW; Al-Ali AK BMC Cardiovasc Disord; 2020 Jun; 20(1):268. PubMed ID: 32493215 [TBL] [Abstract][Full Text] [Related]
30. The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. Price MJ; Tantry US; Gurbel PA Rev Cardiovasc Med; 2011; 12(1):1-12. PubMed ID: 21546883 [TBL] [Abstract][Full Text] [Related]
31. Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel. Novkovic M; Matic D; Kusic-Tisma J; Antonijevic N; Radojkovic D; Rakicevic L Eur J Clin Pharmacol; 2018 Apr; 74(4):443-451. PubMed ID: 29260275 [TBL] [Abstract][Full Text] [Related]
32. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. Mega JL; Simon T; Collet JP; Anderson JL; Antman EM; Bliden K; Cannon CP; Danchin N; Giusti B; Gurbel P; Horne BD; Hulot JS; Kastrati A; Montalescot G; Neumann FJ; Shen L; Sibbing D; Steg PG; Trenk D; Wiviott SD; Sabatine MS JAMA; 2010 Oct; 304(16):1821-30. PubMed ID: 20978260 [TBL] [Abstract][Full Text] [Related]
33. Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease. Hokimoto S; Chitose T; Mizobe M; Akasaka T; Arima Y; Kaikita K; Iwashita S; Morita K; Miyazaki H; Oniki K; Matsui K; Nakagawa K; Ogawa H Eur J Clin Pharmacol; 2014 Jun; 70(6):667-73. PubMed ID: 24763934 [TBL] [Abstract][Full Text] [Related]
34. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting. Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445 [TBL] [Abstract][Full Text] [Related]
35. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy. Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y; Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080 [TBL] [Abstract][Full Text] [Related]
36. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis. Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116 [TBL] [Abstract][Full Text] [Related]
37. Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: a meta-analysis based on 23,035 subjects. Mao L; Jian C; Changzhi L; Dan H; Suihua H; Wenyi T; Wei W Arch Cardiovasc Dis; 2013 Oct; 106(10):517-27. PubMed ID: 24080325 [TBL] [Abstract][Full Text] [Related]
38. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648 [TBL] [Abstract][Full Text] [Related]